CSIMarket
 
Neurocrine Biosciences Inc   (NBIX)
Other Ticker:  
 
 
Price: $135.5800 $1.40 1.043%
Day's High: $136.2 Week Perf: 2.21 %
Day's Low: $ 133.17 30 Day Perf: -3.85 %
Volume (M): 777 52 Wk High: $ 143.35
Volume (M$): $ 105,386 52 Wk Avg: $109.83
Open: $134.25 52 Wk Low: $89.04



 Market Capitalization (Millions $) 13,706
 Shares Outstanding (Millions) 101
 Employees 1,000
 Revenues (TTM) (Millions $) 1,887
 Net Income (TTM) (Millions $) 250
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 28

Neurocrine Biosciences Inc
Neurocrine Biosciences Inc.
is a biopharmaceutical company that is focused on the research, development, and commercialization of treatments for neurological and endocrine-related diseases and disorders.
The company was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences has a strong portfolio of products in various stages of development, including several that have received regulatory approval in the United States and other international markets.
One of its most successful products is Ingrezza, a drug that is used to treat tardive dyskinesia, a condition characterized by involuntary muscle movements.
Ingrezza was approved by the FDA in 2017 and has since become the leading drug in the market for the treatment of tardive dyskinesia.
Neurocrine Biosciences also has several other products in its pipeline, including Ongentys, a drug for the treatment of Parkinsones disease, which was approved by the FDA in 2020.
In addition to its focus on commercializing drugs for neurological and endocrine disorders, Neurocrine Biosciences also invests heavily in research and development.
The company has a strong commitment to discovering and developing new therapies for conditions that have few or no treatment options.
Overall, Neurocrine Biosciences Inc.
is a leading biopharmaceutical company that has been making significant contributions to the field of medicine by developing innovative treatments for neurological and endocrine-related disorders.
With a strong pipeline of products and a commitment to research and development, the company is well-positioned for future growth and success.


   Company Address: 12780 El Camino Real, San Diego, 92130 CA
   Company Phone Number: 617-7600   Stock Exchange / Ticker: NASDAQ NBIX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurocrine Biosciences Inc

Neurocrine Biosciences Inc Tops Charts with Remarkable Financial Growth in 2023

Neurocrine Biosciences Inc has shown impressive growth in their most recent fiscal period, with both income and revenue seeing significant increases year on year. Income jumped by 61.33% to $1.37 per share, while revenue increased by 25.049% to $515.20 million. This growth outpaced many of their peers in the Biotechnology & Pharmaceuticals industry, where the average revenue growth was just 9.77% in the fourth quarter of 2023 compared to the same period a year before.
The company has also seen strong sequential growth, with earnings per share soaring by 67.24% from $0.82 per share and revenue growing by 3.288% from $498.80 million. Net earnings for the fiscal interval ending December 31, 2023 increased by 65.96% to $147.700 million compared to the same period a year ago. Neurocrine Biosciences Inc has highlighted their improving profit margins, with net margin rising to 28.67% and operating margin edging up to 29.17%.

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc Reports Impressive Revenue and EPS Growth During Third Quarter of 2023 Earnings Season

Neurocrine Biosciences Inc, a biotechnology company trading on the NASDAQ, has experienced a decline in its stock price over the past 5 trading days. With a decrease of -2.28%, the year-to-date performance stands at -10.13%. However, despite this recent decline, the stock is still performing reasonably well, currently trading 1.6% above its 52-week average.
During the most recent fiscal period, Neurocrine Biosciences Inc saw a significant increase in its revenue. Revenue grew by a remarkable 28.59% to reach $498.80 million. The company also witnessed a rise in income, which grew by 18.84% to $0.82 per share. Both the revenue and income figures surpassed the numbers reported in the comparable period from the previous year. In contrast, earnings per share (EPS) fell by -13.68% from $0.95 per share in the previous financial reporting period. Despite this decline, revenue advanced by 10.183% from $452.70 million.

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc Reports Remarkable Business Improvement in Q2 2023; Posts Positive Earnings Per Share and Significant Revenue Advancement Against Industry Trend

Neurocrine Biosciences Inc (NBIX) has shown impressive financial results for the interval closing June 30, 2023, marking a significant turnaround. The company has displayed a positive Income per Share of $0.95 compared to a negative $0.18 per share the previous year, while earnings per share have also turned positive, increasing from a negative $0.79 per share in the preceding reporting season. Additionally, revenue has soared by a considerable 19.699% to $452.70 million from $378.20 million compared to the same reporting season a year ago, and sequentially, there has been a 7.683% advancement from $420.40 million.
This performance sets NBIX apart from its peers in the Biotechnology & Pharmaceuticals industry, as many of them are currently experiencing a decline in top-line revenue. NBIX's revenue growth shows its resilience and ability to thrive despite challenging industry conditions. Furthermore, the company has reported a net income of $95.500 million in the financial interval closing June 30, 2023, a significant improvement from a net deficit of $-16.900 million during the same reporting season a year ago.

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc has Slipped into minus at NBIX in the fiscal span ending March 31 2023

The stock market has been buzzing with excitement over the recent announcement from Neurocrine Biosciences Inc. As we head into the second quarter of 2023, the company has reported a return on equity of 4.02%, which outperforms their previous average of -4.05%. This is certainly a promising result for investors and stakeholders alike.
While the decreasing net income may have led to a slight drop in ROE relative to the previous quarter, it is worth noting that Neurocrine Biosciences Inc is still performing well within the biotechnology and pharmaceutical industry. While there were nine companies that had a higher return on equity, the overall ranking of Neurocrine Biosciences Inc has advanced in the quarter, moving from 1787 to 1486.






 

Neurocrine Biosciences Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Neurocrine Biosciences Inc does not provide revenue guidance.

Earnings Outlook
Neurocrine Biosciences Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com